Back to Search
Start Over
PSMA PET/CT for Response Assessment of 177Lu-PSMA Therapy.
- Source :
- Seminars in Nuclear Medicine; Jan2024, Vol. 54 Issue 1, p69-76, 8p
- Publication Year :
- 2024
-
Abstract
- Prostate-specific membrane antigen (PSMA) PET/CT has been widely integrated into the management of prostate cancer (PCa) patients with biochemical recurrence, is increasingly used for initial staging in high-risk patients prior to surgery or to identify candidates for PSMA-targeted radioligand therapy (RLT). To date, monitoring response in PCa patients in prospective studies remains the domain of conventional imaging, such as magnetic resonance/CT or bone scintigraphy. With the increasing use of PSMA-targeted PET/CT in PCa, however, varying criteria based on molecular imaging have been established to define progressive disease, including "PSMA PET Progression Criteria," "Response evaluation criteria in PSMA PET/CT (RECIP 1.0)" or consensus statements of respective societies. In the present review, we will discuss the current status of PSMA PET/CT for response monitoring, focusing on PSMA RLT with [<superscript>177</superscript>Lu]Lu-labeled PSMA ligands, along with a head-to-head comparison of recently published response criteria. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 00012998
- Volume :
- 54
- Issue :
- 1
- Database :
- Supplemental Index
- Journal :
- Seminars in Nuclear Medicine
- Publication Type :
- Academic Journal
- Accession number :
- 174033586
- Full Text :
- https://doi.org/10.1053/j.semnuclmed.2023.06.003